The effectiveness of Pelvic Floor Muscle Training through Immersive Virtual Reality for the treatment of Stress Urinary Incontinence based on the impact on the quality of life in adult women elite athletes - A randomized controlled trial - by Arumí Trujillo, Clàudia
  
 
 
 
UNIVERSITAT DE LLEIDA 
 
 
 
Done by: 
Clàudia Arumí Trujillo  
 
FACULTAT D’INFERMERIA I FISIOTERÀPIA 
Grau en Fisioteràpia 
 
Tutor: Francesc Valenzuela Pascual 
 
Final degree assignment  
 
2017/18 
 
25th May 2018 
 
 
 
 “The effectiveness of Pelvic Floor Muscle Training 
through Immersive Virtual Reality for the treatment of 
Stress Urinary Incontinence based on the impact on the 
quality of life in adult women elite athletes”  
 
- A randomized controlled trial -  
 
 
 
2 
 
INDEX 
TABLE INDEX ....................................................................................................................... 4 
FIGURE INDEX ..................................................................................................................... 5 
ACRONYM INDEX ................................................................................................................ 6 
RESUMEN ............................................................................................................................ 7 
ABSTRACT ........................................................................................................................... 8 
INTRODUCTION ................................................................................................................... 9 
1 THEORICAL FRAMEWORK .........................................................................................10 
1.1 ANATOMY AND PHISIOLOGY ..............................................................................10 
1.1.1 URINARY WOMEN SYSTEM .........................................................................10 
1.1.2 REPRODUCTIVE SYSTEM ............................................................................11 
1.1.3 INNERVATION CONTROL OF THE URINATION ...........................................11 
1.1.4 URINATE PHISIOLOGY .................................................................................11 
1.1.5 FEMALE PELVIC FLOOR ANATOMY ............................................................14 
1.2 URINARY INCONTINENCE ...................................................................................17 
1.2.1 RISK FACTORS ..............................................................................................18 
1.3 TYPES OF URINARY INCONTINENCE .................................................................18 
1.3.1 STRESS URINARY INCONTINENCE (SUI) ....................................................18 
1.3.2 URGENCY URINARY INCONTINCE (UII) ......................................................19 
1.3.3 MIXED URINARY INCONTINENCE (MUI) ......................................................19 
1.4 STRESS URINARY INCONTINENCE PHISIOPATOLGY. ABDOMINO-PELVIC-
DIAPHRAGM SYSTEM. ...................................................................................................19 
1.4.1 FUNCTIONAL RELATION BETWEEN SYSTEMS: TRANSVERSALITY AND 
VERTICALITY ...............................................................................................................20 
1.5 POPULATION ........................................................................................................21 
1.6 DESCRIPTION OF THE INTERVENTION .............................................................22 
1.6.1 PELVIC FLOOR MUSCLE TRAINING (PFMT)................................................22 
1.6.2 BIOFEEDBACK ...............................................................................................24 
1.6.3 IMMERSIVE VIRTUAL REALITY ....................................................................25 
2 JUSTIFICATION............................................................................................................27 
3 HYPOTHESIS ...............................................................................................................28 
4 OBJECTIVES ................................................................................................................28 
4.1 PRIMARY OBJECTIVE ..........................................................................................28 
4.2 SECONDARY OBJECTIVES .................................................................................28 
5 METHODOLOGY ..........................................................................................................29 
5.1 DESIGN .................................................................................................................29 
5.2 STUDY SUBJECTS ...............................................................................................30 
3 
 
5.2.1 INCLUSION CRITERIA ...................................................................................31 
5.2.2 EXCLUSION CRITERIA ..................................................................................31 
5.3 STUDY VARIABLES ..............................................................................................33 
5.3.1 TYPES OF OUTCOME MEASURES ..............................................................33 
5.4 DATA COLLECTION AND ANALYSIS ...................................................................37 
5.5 GENERALIZATION AND APPLICABILITY .............................................................37 
5.6 STATISTICAL ANALYSIS ......................................................................................38 
5.7 INTERVENTION PLAN ..........................................................................................40 
5.7.1 SYSTEM CHARACTERISTICS ..........................................................................40 
5.7.2 SYSTEM ARCHITECTURE ................................................................................41 
5.7.3 FIRST ASSESSMENT ........................................................................................42 
6 CALENDAR ...................................................................................................................47 
7 LIMITATIONS AND BIAS ..............................................................................................48 
7.1 FUTURE INVESTIGATIONS ..................................................................................49 
8 ETHICAL ASPECTCS AND DIFFUSION ......................................................................49 
8.1 ADVERSE EFFECTS .............................................................................................50 
9 STUDY ORGANIZATION ..............................................................................................51 
9.1 RECORD OF DATA AND PRESERVATION OF DOCUMENTS.............................52 
9.2 PUBLICATION CONDITIONS ................................................................................52 
10 BUDGET....................................................................................................................52 
11 BIBLIOGRAPHY ........................................................................................................54 
12 ANNEX ......................................................................................................................59 
12.1 OPEN CLINICA ......................................................................................................59 
12.2 BASELINE SOCIODEMOGRAPHIC TABLE ..........................................................60 
12.3 UROGYNEACOLOGICAL ANAMNESIS ................................................................61 
12.4 SUMMARY RECOMMENDATIONS .......................................................................63 
12.5 FACT SHEET FOR PATIENTS ..............................................................................64 
12.6 INFORMED CONSENT FOR PATIENTS ...............................................................68 
12.7 ICIQ – SF ...............................................................................................................69 
12.8 PAD TEST 1H ........................................................................................................70 
12.9 INCONTINENCE SEVERITY INDEX ......................................................................71 
12.10 EAU RECOMMENDATIONS ..............................................................................72 
 
 
 
4 
 
TABLE INDEX 
 
Table 1. Innervation control of the urination ..........................................................................11 
Table 2: Modified Oxford rating scale for the pelvic floor musculature ..................................36 
Table 3.  Approximate equivalences between the scale of Laycock assessment and the 
pressure measured by the perineometer in mm Hg ..............................................................36 
Table 4.  Schedule of enrolment, interventions, and assessments SPIRIT. ..........................47 
Table 5. Facilities and rrhh budget .......................................................................................53 
Table 6. Physiotherapist’s material budget ...........................................................................53 
Table 7. Office material budget .............................................................................................53 
Table 8.  Baseline sociodemographic characteristics ...........................................................60 
Table 9. Summary of Recommendations in UI assessment ..................................................63 
Table 10. Pad test 1 hour standardization ............................................................................70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
FIGURE INDEX 
Figure 1. The pelvis and perineum contain and support terminal parts of the gastrointestinal, 
urinary, and reproductive systems. .......................................................................................11 
Figure 2. Urethral pressure and Vesical pressure during the filling urination phase ..............12 
Figure 3. Urethral pressure and vesical pressure during emptying urination phase. .............13 
Figure 4. Bladder filling and emptying diagram. ....................................................................13 
Figure 5. Ligaments structure: P: pubis; U: uterus; V: vagina; S: sacrum; AT: tendinous arch; 
PU: pubourethral ligament; UP: urethra-pelvic ligament; US: uterosacral .............................14 
Figure 6. Accessory muscles in charge of structural support ................................................15 
Figure 7. Urogenital diaphragm. ...........................................................................................15 
Figure 8. Pelvic diaphragm ...................................................................................................16 
Figure 9. Perineal membrane ...............................................................................................17 
Figure 10. Springboard theory. .............................................................................................21 
Figure 11. Diagram of the project architecture ......................................................................42 
Figure 12. Peritron device ....................................................................................................45 
Figure 13. Electrostimulation catheter ..................................................................................48 
Figure 14.  Pre-appointment patient history ..........................................................................61 
Figure 15. Pelvic Floor Pathway Clinic .................................................................................62 
Figure 16. International Consultation on Incontinence Questionnaire ...................................69 
Figure 17. Incontinence severity index questionnaire ...........................................................71 
Figure 18. EAU Recommendations for behavioural and physical therapies ..........................72 
 
 
 
 
 
 
 
 
 
 
6 
 
ACRONYM INDEX 
 ICS: International Continence Society  
 IUA: International Urogyneacological Association  
 UI: Urinary Incontinence  
 PFMT: Pelvic floor muscle training  
 ONI: National Incontinence Observatory 
 SUI: Stress urinary incontinence  
 BF: Biofeedback 
 RCT: Randomized controlled trial 
 SR: Systematic Reviews  
 IVR: Immersive virtual reality  
 EAU: European Association of Urology 
 ICIQ-SF: International Consultation on Incontinence questionnaire - short form  
 NICE: National Institute for Health and Care Excellence 
 ISI: Incontinence severity index  
 MVC: Maximal voluntary contraction  
 QoL: Quality of life  
 SPSS: Statistical Package for the Social Sciences  
 IRB: Institutional review board 
 EC: Ethical committee 
 NHS: National Health Service 
 TTP: Train-to-play  
 
 
 
 
 
 
 
 
7 
 
RESUMEN 
Pregunta de investigación: ¿Es eficaz el entrenamiento muscular del suelo pélvico 
con biofeedback mediante un programa de realidad virtual inmersiva para mejorar la 
calidad de vida de mujeres deportistas de élite en edad adulta?   
Objetivo: Evaluar la efectividad del entrenamiento muscular del suelo pélvico con 
biofeedback mediante un programa de realidad virtual inmersiva para mejorar la 
calidad de vida en mujeres deportistas de élite en edad adulta.  
Metodología: Diseño del estudio: Se diseñará un ensayo clínico controlado aleatorio 
de doble ciego en un número total de 64 mujeres que padecen incontinencia urinaria 
de esfuerzo. Muestra y aleatorización: Las participantes, atletas del Car de Sant Cugat 
en edad adulta, serán asignadas al azar y de forma equivalente; 32 participantes en 
el grupo control y 32 participantes en el grupo experimental. Intervención: Las 
pacientes serán aleatorizadas y asignadas para realizar los ejercicios de 
entrenamiento muscular del suelo pélvico con biofeedback y mediante un programa 
de realidad virtual inmersiva (grupo experimental) o para realizar los ejercicios de 
entrenamiento muscular del suelo pélvico con solo biofeedback (grupo de control). 
Mediciones: Para el objetivo principal se utilizará el ICIQ-SF (International 
Consultation of Incontinence Questionnaire-Short Form) para medir el impacto de la 
incontinencia urinaria de esfuerzo en la calidad de vida. Las medidas de los objetivos 
secundarios evaluarán; las fugas de orina mediante el Pad Test, la gravedad de la 
incontinencia urinaria mediante el cuestionario ISI (Incontinence severity index), la 
fuerzo muscular del suelo pélvico mediante el perineometro y para medir la adherencia 
al tratamiento se tendrá en cuenta las veces que la paciente accede a la aplicación 
informática de ejercicios de rehabilitación. Calendario y evaluaciones: La intervención 
durará un año con una evaluación al comienzo del proceso y en los meses 3, 6 y 12. 
Palabras clave: fisioterapia, incontinencia urinaria de esfuerzo, entrenamiento 
muscular del suelo pélvico, deportistas de élite, nuevas tecnologías. 
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ABSTRACT 
Research question: Is it effective the pelvic floor muscle training with biofeedback 
and using an immersive virtual reality programme to improve quality of life in adult elite 
women athletes?  
Objective: To evaluate the effectiveness of pelvic floor muscle training with 
biofeedback using an immersive virtual reality programme to improve quality of life in 
adult elite women athletes.  
Methods: Study design: A double blind randomized controlled clinical trial with a total 
number of 64 women who suffer from stress urinary incontinence. Sample and 
randomization: The adult women elite athletes from Sant Cugat CAR will be assigned 
randomly and equally, 32 subjects in the control group and 32 subjects in the 
experimental group. Intervention: Patients will be randomly assigned either to the 
pelvic floor muscle training with biofeedback using an immersive virtual reality by an 
application programme (experimental) or to the pelvic floor muscle training with 
biofeedback alone by the same application programme (control). Measurements: The 
primary outcome will be the quality of life measured with International Consultation on 
Incontinence Questionnaire - Short Form. Secondary outcomes will be the urine 
leakage measured by Pad Test, urinary incontinence severity measured by 
Incontinence Severity Index test, pelvic floor muscle strength measured by 
perineometry and to measure the treatment adherence it will be taken into account the 
times that the patient accesses the application. Calendar and assessments: the 
intervention will last one year with evaluations at the beginning of the process and in 
the 3rd, 6th and 12th month.  
Key words: physiotherapy, stress urinary incontinence, pelvic floor muscle training, 
elite athletes, new technologies.  
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INTRODUCTION  
The International Continence Society (ICS) and the International Urogynecological 
Association (IUA) define urinary incontinence (UI) as a symptom, namely “the 
complaint of any involuntary loss of urine” (1).  
The urinary incontinence is an underdiagnosed pathology and in many cases 
undertreated or not properly treated. Furthermore, not only is a medical problem but 
also psychosocial problems, causing a concealment because of fear to social rejection 
(2) and negative self-perception (3). The wide range of published prevalence of UI 
reflects differences in its definition, the methodology and demographics of the studies 
population (4). However, the prevalence figures are not exact to reflect the true 
incidence of this pathology since the shame and other factors may lead to inaccurate 
results (3). 
It has been published that UI is twice as common in women as in men. While in Spain 
the average women prevalence is 24% in men is 7% (2). Women stop or diminish their 
activity and social participation (1). It has been reported that there is an association 
between physical exertion and urinary loss. An increase of intra-abdominal pressure 
due to physical exertion, leads to an increase of intra-vesical pressure and, if it is higher 
than intraurethral pressure, the resulting is an urine leakage. That is why many athletic 
women suffer from this pathology (1).  
 
Moreover, economic costs of urinary incontinence are considerable (5), which in 1996 
in Spain supposed 120 millions of euros, and that sometimes are financed by the 
patients and in other cases by the National Health Service (6). Furthermore, in 2015 
absorbents and sanitary towels for urinary incontinence were the most important 
medical devices consumption in containers (7.5 million) and in amount (288.9 million 
euros) (7).  
Nonetheless, there is no consensus on the optimum type, duration, or frequency of 
pelvic floor muscle training (PFMT), which is the first line of conservative treatment (8). 
The actual evidence is insufficient to make any robust recommendation about the best 
approach to PFMT (9), so it is clear the need of doing more research in this field 
because it will be able to provide new knowledge that will help improving the quality of 
life of the patients who suffer from it. 
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1 THEORICAL FRAMEWORK 
1.1 ANATOMY AND PHISIOLOGY  
1.1.1 URINARY WOMEN SYSTEM  
 
The body absorbs the nutrients to maintain every corporal function. Once the body 
soaks up what it needs, the urinary system synergy works with the lungs, the skin and 
the intestines to eliminate the residues in order to maintain a chemical and water 
equilibrium (10). 
Urinary system comprises a series of organs, tubs muscles and nerves which work 
together to produce, keep and transport urine. Urinary system consists of two kidneys, 
two ureters, the bladder, two sphincters and the urethra (10): 
- Kidneys: Located at the back of the abdomen, beside the vertebral column. 
Kidneys eliminate the urea through the nephrons. Urea, water and other 
residues conform the urine. 
- Ureters: Tubular organs from the kidneys to the bladder, responsible of urine 
transport. They have between 8 and 10 inches of length.  
- Bladder: Muscular organ situated above the pelvis, responsible to keep the 
urine until it is voluntary evacuated. It is formed by the detrusor muscle which is 
the responsible of the contraction. In normal conditions it keeps among 400cc 
of urine.  
- Sphincters: They help keeping the urine and avoid the dripping. The intern 
involuntary sphincter it is formed by straight muscle and the voluntary external 
sphincter it is formed by stretch-marked muscle.  
- Urethra: Tubular organ which communicates the bladder with the exterior 
allowing the urine evacuation.  
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1.1.2 REPRODUCTIVE SYSTEM  
Elements: vulva (clitoris), uterus and vagina, fallopian tubes, ovaries, glands of Skene 
and Bartholin (11). 
 
1.1.3 INNERVATION CONTROL OF THE URINATION  
 
Sympathetic  nucleus Hypogastric nerve (D10-L1) Internal sphincter 
Parasympathetic nucleus Pelvic nerve (S2-S3-S4) Detrusor 
Somatic nucleus Pudendal nerve (S3-S4) External sphincter 
Table 1. Innervation control of the urination (11). 
1.1.4 URINATE PHISIOLOGY (12) 
 
The micturition is defined as: the bladder emptying when it fills full of its physiology 
capacity.  
Conditions for a normal micturition: 
 Voluntary 
 Complete 
 No pain 
 Capacity to interrupt  
 Separated > 2 hours  
 Without urgency  
 Occasionally 
It consists of two phases: fill phase and empty phase 
Figure 1. The pelvis and perineum contain and support terminal parts of the 
gastrointestinal, urinary, and reproductive systems (11). 
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 FILL PHASE:  
o Bladder relaxation  
o Detrusor relaxation  
o Internal sphincter (involuntary) in contraction  
o External sphincter (voluntary) in contraction  
To be continent during the filling phase the urethral pressure (UP) has to be > than the 
vesical pressure (VP)  
 
 
 
 
 
 
 
 
 
 
 EMPTY PHASE:  
o Detrusor contraction 
o Internal sphincter relaxation 
o External sphincter relaxation   
During the emptying phase UP < VP [Voluntary micturition: UP – VP = +] 
Figure 2. Urethral pressure and Vesical pressure during the filling urination 
phase (12).  
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Figure 4. Bladder filling and emptying diagram. 
Figure 3. Urethral pressure and vesical pressure during emptying urination phase (12). 
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1.1.5 FEMALE PELVIC FLOOR ANATOMY  
1.1.5.1 LIGAMENTS STRUCTURE 
The most important ligaments are (13):  
a) Pubourethrals: They have its origin in the low rim of the pubis. They are inserted 
sideways in pelvic fascia arch at the level of the average third of the urethra. 
b) Urethro-pelvics: They have its origin sideways in the pubourethral ligaments and 
they are inserted in the central region, being the main suburethral support.  
They act as a whole with the pubourethral ligaments in the mechanisms of 
continence and micturition. 
c) Uterosacrals: They have its origin sideways in the front of the sacrum and they 
are inserted in fascia pubocervical in the vaginal apex. 
The region between the pubourethral ligaments and the vesical neck is named the 
area of critical elasticity for its dynamic and fundamental role in the micturition 
mechanism and of urinary continence. 
 
 
 
 
 
Figure 5. Ligaments structure: P: pubis; U: uterus; V: vagina; S: sacrum; AT: tendinous arch; PU: 
pubourethral ligament; UP: urethra-pelvic ligament; US: uterosacral (13). 
 
15 
 
1.1.5.2 PERINEAL MUSCULAR SYSTEM (ACTIVE SUPPORT)   
The structure and the function of the pelvic floor is controlled by 4 muscular groups: 
(11,14). 
1) Pelvic wall: Obturator + piriform (lateral wall). These muscles originate in the pelvic 
cavity and attach to the femur.  
2) Accessory: Gluteus maximus + adductors (support structure) work synergy with 
levator ani.  
 
3) Urogenital diaphragm:  
a. In the front: Ms. Bulbospongiosus + Ischiocavernosus + Superficial 
Transverse.  
b. Middle: perineal body or centre tendinous of perineum (from the vagina to 
the rectum). 
c. Back: Anal sphincter. 
d. It is also included the extern 
sphincter and the deep 
transversus of perineum, 
located between the two 
ischiopubic branches.  
 
Figure 6. Pelvic wall  muscles in charge of structural support (11).  
Figure 7. Urogenital diaphragm (11). 
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4) Pelvic diaphragm:  
It takes from the back of pubis until coccyx. It is concave from the top and 
convex from the bottom and inside it contains the pelvic organs. It is innervated 
by S2-S3-S4. Its 70% of fibbers are type I and 30% type II. 
a. Levator ani (Pubococcygeus + Iliococcygeus + Puborectalis). It is an 
important muscle for the support of the pelvic viscera and it maintains the 
closure of rectum and vagina. It is innervated by branches from the anterior 
ramus of S4 and by branches of the pudendal nerve (S2 to S4).  
 Pubococcygeus: Originates at pubis and inserts at coccyx.  
 Iliococcygeus: Originates at Internus Obturator and inserts at coccyx. 
 Puborectalis: Originates at internal and lower side of pubis, and blend 
together posterior to the vagina and around the anal aperture. 
 Posterior to the anal aperture, the muscles come together as a 
ligament called the anococcygeal ligament and attaches to the 
coccyx.   
b. Coccygeus: It completes the posterior part of the pelvic diaphragm. It is 
attached to the tips of the ischial spines and to the lateral margins of the 
coccyx and sacrum. It is 
innervated by branches from 
the anterior rami of S3 and 
S4.  
Both muscular layers explained 
(superficial and deep layer) are situated 
at different levels so they have different 
shape and orientation. 
 
 
  
 
 
Figure 8. Pelvic diaphragm (11). 
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5) The perineal membrane: It is a thick, triangular fascial sheet, that fills the space 
between the arms of the pubic atch, and has a free posterior border. The perineal 
membrane is related above to a thin space called the deep perineal pouch (deep 
perineal space), which contains a layer of skeletal muscle and various 
neurovascular elements. 
1.2 URINARY INCONTINENCE  
Urinary incontinence is defined by the ICS and the IUA as any non-voluntary loss of 
urine (1).  
It is considered as a disease by the OMS since 1998, due to its repercussion in quality 
of life (QoL) and its psychosocial affectation (15). 
The latest study in 2009 done by the National Incontinence Observatory (ONI) based 
on a systematic review (SR), concluded that around 6.000.000 people in Spain could 
suffer urinary incontinence. What surprises the most is the poor index of consultation 
because women take 3 years until they turn to the doctor. Nowadays, 80% of the 
patients who turn to any specialist improve or cure the pathology (16). However, the 
number is not exactly due to the shame people feel to face the pathology and how they 
try to hide it (2,15).  
Furthermore, as it is mentioned above, there are a lot of studies published about 
prevalence for UI with a wide range. This is because of differences in the definition, in 
Figure 9. Perineal membrane (11). 
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epidemiologic methodology, and in demographic characteristics among the studies 
(4,15). 
Worldwide it is estimated a prevalence of UI in women which vary in most studies 
between 24% to 45% (2,3). Talking about men, the literature about UI is still scarce. It 
is reported that UI occur twice as common in women as in men (4). 
The consequences of UI are not only physical, it also includes social, sexual and 
psychological effects which produces a decrease on women’s quality of life, who tend 
to diminish their activity and social participation (1).  
1.2.1 RISK FACTORS  
The most important risk factors are pregnancy and vaginal delivery, although they 
become less important with increasing age (4). Age is one of the most well-known risk 
factors for pelvic floor dysfunction and the only which it is not modifiable an directly 
related to the incidence of stress urinary incontinence (SUI) and pelvic organ prolapse 
(17). Other risk factors reported in different studies are; diabetes mellitus, oral 
oestrogen, obesity, the use of forceps in a vaginal delivery, the amount of sport 
practice, respiratory disease and childhood enuresis (4,17,18). 
1.3 TYPES OF URINARY INCONTINENCE 
There are different types of UI classified according to the symptoms the women report, 
the signs observed by the clinicians and on the basis of urodynamic studies (3). The 
ICS defines generally 3 types of UI:  
1.3.1 STRESS URINARY INCONTINENCE (SUI)  
It is defined as the involuntary urine leakage with physical exercise or doing some kind 
of exertion such as running, jumping, lifting, or with coughing or sneezing (3,5). 
It is reported that SUI is the consequence of anatomical defects in bladder and urethra 
supporting structures or because of a dysfunction of the neuromuscular components 
that help control the urethral sphincter or urethral pressure. As a result, the urethra is 
not well closed during the exertion and this fact results in urine loss (3,5). 
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1.3.2 URGENCY URINARY INCONTINCE (UII)  
It is defined as involuntary leakage preceded by a sudden need to urinate. Women 
describe it as “sudden, compelling desire to pass urine which is difficult to defer”. This 
condition usually occurs due to a contraction of the detrusor muscle which increases 
bladder pressure. It is not clear what is the cause, often there is not any, but sometimes 
it is resulting from a neurological disorder (3,5). 
It is frequent that women report other symptoms as frequency (urinate more often than 
usually) and nocturia (interrupted sleep because of the need to void) (5). 
1.3.3 MIXED URINARY INCONTINENCE (MUI)  
It is defined as the combination of both stress and urgency symptoms (3). 
1.4 STRESS URINARY INCONTINENCE PHISIOPATOLGY. ABDOMINO-PELVIC-
DIAPHRAGM SYSTEM.  
SUI is defined as the involuntary urine leakage associated with a physical effort. It is 
produced when vesical pressure overtakes urethral pressure. Actually, there are two 
accepted mechanisms which can cause SUI (19,20): 
1. Intrinsic sphincter deficiency: Urethra lacks the capability to stay closed in repose, 
it keeps constantly opened.  
2. Urethral hypermobility: Implies a weakening of the supporting structures of the 
pelvic floor (muscles, ligaments, nerves, connective tissue or a combination 
thereof). Urethra keeps its light closed during repose but during abdominal 
increasing pressures the urethra descends and urethral neck opens. As a 
consequence it causes the urine leakage. It is in these cases where the proper 
functioning of the abdomino-pelvic-diaphragmatic system, composed of the 
thoracic diaphragm, the abdominal wall and the pelvic floor, plays a fundamental 
role and where physiotherapy can act effectively.  
In summary, there are three factors that directly affect in the development of urethral 
hypermobility and therefore in the SUI (19): 
1. Hypertonia of the thoracic diaphragm: that increases the abdominal pressure.  
2. Incompetent abdominal wall: that will direct the pressures towards the anterior 
area of the pelvic cavity which is the weakest zone. 
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3. Incompetence of the pelvic floor that allows an excessive visceral mobility. 
1.4.1 FUNCTIONAL RELATION BETWEEN SYSTEMS: TRANSVERSALITY AND VERTICALITY  
 
 ABDOMINAL WALL (19): 
The abdominal hyper-pressure resulting due to an effort, generates a vertical force 
which falls on the perineum. 
Transverse abdominal muscle acts as a point of support during the abdominal pressure 
generated because of the descending thoracic diaphragm during efforts as coughing, 
sneezing, catching weight, etc.  
Pelvic floor in order to balance out this mechanic stress, generates a force towards 
anterior and above. The result of both forces, if there is a correct functional pelvic floor, 
is towards back and bottom, which is the strongest part of perineum (fibrous nucleus 
of the perineum, sacrum zone and coccyx).  
However, if there is not a competent abdominal wall, the result of the force is towards 
anterior perineum, where there is the vagina and the bladder, causing more risk of 
suffering SUI because it is the weakness zone. 
 THORACIC DIAPHRAGM (19): 
There are many daily factors which increase the abdominal pressure. The thoracic 
diaphragm is the power unit of these increases. It descends during the inspiration and 
ascends during the exhalation. In an effort situation, it descends and pushes the 
viscera to the bottom. So for example, the cough of a person with a hypertonic thoracic 
diaphragm will increase more the pressure to the abdominal cavity than a person with 
a normal muscle tone.  
 SPRINGBOARD THEORY (20): 
According to this theory, the alterations of the tension applied by the muscles and 
ligaments on the fascia of the vaginal wall determine the opening or closing of the 
bladder neck and the urethra. To sum up, when all the factors are correctly working 
there is not SUI but when there are multiple factors badly working it can cause SUI.  
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1.5 POPULATION  
 
SUI appears when urethral pressure is insufficient or outpaced by vesical pressure 
during the moment of realizing a physical effort which produces an increase of 
abdominal pressure (21). 
Repeated pressure actions alter in the short, mid or long term the passive fastening 
structures of the pelvic floor, occasioning urine leaks in detailed effort moments like 
running, jumping, laughing, coughing, sneezing and similar (22).  
Among the activities which generate more intra-abdominal pressure (values higher 
than 30-50 mm Hg are considerate as hyper-pressure) stand out according to 
Valancogne et al. (23): a) abdominal exercises b) athletics c) basketball d) aerobic  
e) tennis. On the opposite side, swimming and cycling are those which less abdominal 
pressure generate (22,24). 
So it seems clear that the prevalence of SUI in women elite athletes is very high and 
depends majority on the type of sport and the training frequency with also other risk 
factors (age, parts, corporal composition, etc.). The most common risk sport factors 
are: 1) training length 2) training frequency 3) number of years realizing sport 4) sport 
impact (22,25,26). 
Different examples of studies in athletes are presented below:  
Figure 10. Springboard theory (11). 
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Eliasson et al. (25) studied a group of female ex-trampolinists (n = 305) and found that 
35% were affected in daily life, 53% reported to be psychologically affected, and 12 % 
stopped exercising because of UI, and what is more important, 76% keep suffering 
leakage also after having finalized their sport practice. The study also confirmed that 
80% of springboard jumpers presented leaks of 28 g. This fact is really important 
because the middle age of these women was 16 years old.  
An example of Spanish athletes, Pérez et al. (22) reported a SUI prevalence of 26,5%, 
while at the direct question only 5 recognised suffering SUI, so it emphasised the thesis 
that some women try to undervalue a grade of SUI.  
Another study realized in two similar groups of women, with the only difference among 
them was the sport practice, demonstrated that 62,8 % of those who practiced sport 
suffered SUI during the sport practice and 60% during daily life. However, only 43 % 
of those who did not practice sport suffered SUI (27). 
Nevertheless, the prevalence could change depending on the sport. This was 
demonstrated by a university athletes group. 144 women were questioned and 28 % 
confirmed leakage during the sport practice, the average age was 19’9 years and it 
was studied 9 different sports. Gymnasts (67%) were the most affected in compare 
with golfers (0%) (28). 
1.6 DESCRIPTION OF THE INTERVENTION 
1.6.1 PELVIC FLOOR MUSCLE TRAINING (PFMT) 
Physical therapies to treat SUI include pelvic floor muscle training (PFMT) with or 
without biofeedback (BF), electrical stimulation, and weighted vagina cones (29).  
Kegel was the first one introducing PFMT as an effective therapy for urinary 
incontinence in women. He published a successful study of 64 cases of female SUI 
where 84 % of his patients were cured, and that is why the treatment became 
widespread after the mid-1900s (3).  
Although Kegel’s studies weren’t controlled and they lacked many outcome measures, 
several randomized controlled trials (RCT) and systematic reviews (SR) have 
confirmed that PFMT is effective for the treatment of SUI and MUI. Now, PFMT is 
recommended as first-line treatment (grade A). However, there are still doubts about 
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long-term outcomes. Cure and improvement rates in RCTs vary between 56% and 
70%. Although there is strong belief in the evidence that PFMT improves, it does not 
abolish the condition. It is reported that 44-69 % women are cured, defined as < 1-2g 
of leakage on pad tests (26,29–31). 
In contrast with other conservative treatments, PFMT seems to be more effective than 
electrical stimulation, oestrogen therapy, or the most common medication used as 
Duloxetina and Oxibutina in the treatment of SUI. It is concluded that electrically 
stimulated muscle contractions in humans are less effective than voluntary 
contractions for strengthening. The same is reported about vaginal cones (29). 
The protocol published about PFMT follows recommendations for general training to 
increase strength of skeletal muscles (1,26,29):  
Nº of repetitions: 8 to 12 repetitions close to maximum during 6-8 seconds in each 
position. 
Rest period: 6 seconds.  
Positions: Lied, biped, kneeled, and sited with legs apart.  
Frequency: Intensive. Some studies report three times per day and others report three 
times per week.  
Duration: The American College of Sports Medicine, based on strength training 
programs, recommends that it should last at least 15-20 weeks because they confirm 
that: the first 8 weeks the changes are neural, followed by muscle hypertrophy due to 
increased volume and number of myofibrils. In most studies the training program 
duration is 12 weeks because it already seems to reduce the urine leakage.  
Bø (32) has summarised three concepts that might explain how PFMT may work: 
1. Conscious PFM pre-contraction during physical stress: 
“The Knack” is defined as the pre-contraction of pelvic floor muscles (PFMs) 
just before physical stress in order to prevent urinary leakage. The patient has 
to contract PFMs before the increase of intra-abdominal pressure and try to hold 
this contraction during the physical stress.  
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2. PFM strength training: 
The purpose is to rise the position of the levator muscle plate in the pelvis in 
order to facilitate the automatic PFMs response to face intra-abdominal 
pressure changes.  
3. Facilitation of PFM contraction trough abdominal muscle contraction: 
It is reported that the contraction of transversus abdominus is accompanied by 
a co-contraction of PFMs. But the role of this abdominal muscle is still unclear 
to treat female urinary incontinence.  
1.6.2 BIOFEEDBACK  
Many women are not aware of how identifying, controlling and coordinating pelvic floor 
muscles or how to avoid a rise in intra-abdominal pressure, so they don’t know how to 
perform PFMT. Biofeedback is a therapy which relays visuals and/or auditory evidence 
of pelvic floor muscle tone using a surface electrode inserted into the vagina (33). Its 
relevance lies in the intention to teach subjects to “bring certain physiologic processes 
under voluntary control” (34).  
Biofeedback by itself is not a treatment for UI but as an adjunct to PFMT provides 
feedback signals on what muscles are contracting, which provides the patient a better 
identification of the correct muscle group training and at the same time increases 
patient’s motivation,  so an improve in self-control of incontinence might result of it (34–
36). 
Hsu et al. (35) carried out a meth-analysis which studied the effects of biofeedback 
assisted pelvic floor muscle training in patients with urinary incontinence after radical 
prostatectomy in compare with pelvic floor muscle training alone. Authors literally 
concluded that:  
“Biofeedback-assisted pelvic floor muscle training exerts immediate-, inter-mediate-, 
and long-term beneficial effects on urinary incontinence compared with pelvic floor 
muscle training alone when urinary incontinence was measured objectively.”  
Pelvic floor muscle exercises are applied either alone (home program or 
clinic/supervised programs) or with BF especially in routine clinical practice and in the 
literature. Furthermore, the EAU defines in its Guidelines of Urinary Incontinence, a 
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Recommendation level “A” the use of BF as an adjunct in women with SUI (annex 
12.10) (36,37).  
1.6.3 IMMERSIVE VIRTUAL REALITY  
Immersive Virtual Reality (IVR) is a computer technology with artificial sensory 
feedback which provides individual experience activities similar to real-like events.  The 
special defining features are “interaction”, referred to the presence of different sensory 
channels (sight, hearing touch, and even smell) and “immersion”, referred to 
involvement of the participant with the virtual environment (38,39).  
It has a high degree of ecological validity (the extent to which an experiment reflects 
the real world), and this increases the probability that the acquired skills transfer to the 
real world. Indeed, it offers many advantages to the therapist. The therapist can 
observe realistic perceptions, reactions and emotions in the patient in a real-like three 
dimensional environment (38,39). 
Immersive virtual reality rehabilitation (IVRR) has three key elements that are important 
in motor learning (38): 
- Repetition.  
- Sensory feedback. 
- Motivation of the subject.  
Virtual reality has previously been used in some training settings, such as flight 
simulation training for pilots and procedural training for surgeons. Talking about health 
care, so far IVR is being used to treat phobias, post-traumatic stress disorders, and 
body image disorders. A SR on the treatment of stroke vascular brain, concludes that 
the treatment only with virtual reality does not show significant results on the functional 
improvement of upper limb compared to conservative treatment, but classifies the level 
of evidence of the studies as low quality and highlights the need to conduct more 
studies of better quality for the use of IVR in the field of rehabilitation (40). 
Botelho et al. (33) designed a virtual reality intervention protocol conducted on 
nulliparous women without urinary symptoms and postmenopausal women with mixed 
urinary symptoms. The study concludes that “virtual reality program promoted an 
increase in pelvic floor muscles contractility and a decrease in postmenopausal urinary 
symptoms” but it lacks of high methodology.  
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Elliot et al. (34) already did the quasi-experimental pre-test, post-test pilot study to 
evaluate “the feasibility of using a PFMT/VRR program to treat MUI in older woman, to 
evaluate its effectiveness on symptoms and quality of life and to gather quantitative 
information regarding patient satisfaction with the PFMT/VRR training program”. 
Results are not published yet.  
On the other hand, an article published in 2017 by the International Urogynecology 
Journal, reported that (41):   
“European urogyneacologist and physical therapists welcome innovative treatment 
options for the conservative treatment of SUI such as portable wireless biofeedback 
and serious gaming. Scientific evidence is considered a prerequisite to incorporate 
such innovations into clinical practice.” 
Besides, a metha-analysis from 2017 on neurorehabilitation concluded that some 
specific games are more effective in improving motor upper limb and 
movement/balance functions compared to conventional rehabilitation (42).  
However, some authors declare in their studies that there is insufficient evidence to 
reach conclusions about the effect of IVR on other functions, which are the most 
significant characteristics of IVR and that there is not enough knowledge about effects 
in the longer term (39). 
 
Otherwise, it is reported that any training program diminish with time if PFMs have not 
reached an automatic level. It is shown that there is between 5-10% loss of muscle 
strength per week after training cessation. Additionally, some women may find the 
exercise hard to conduct on a regular basis. It is considered that to maintain strength 
gains or slow strength loss, the intensity should be maintained but the volume and the 
frequency can be reduced, so IVR could be a help tool to keep patient’s motivation and 
avoid training cessation (30). 
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2 JUSTIFICATION 
Involuntary urine loss has been reported to occur in about 5-69% of women. Recent 
studies conducted by the ONI report the high prevalence of people suffering from 
urinary incontinence in this country (2,4). 
In regard to the treatment, many systematic reviews and the European Association of 
Urology evidences PFMT as the first-line treatment (grade A)  (3,4). 
However, it should not be forgotten that one of the principal derivate problem of this 
pathology is the high economic spending in sanitary towels and containers (6,43). 
Many studies carried out, evidenced the high prevalence of SUI in elite women 
athletes. Urinary incontinence is a socially embarrassing condition, not only causing 
withdrawal from social situations and a decrease in quality of life but also may lead to 
withdrawal from regular physical and fitness activities (29). 
 
So far, there is no agreement on the most appropriate exercise protocol, so it seems 
significant to do more research about it. Moreover, no RCTs have yet been conducted 
on the effect of PFMT on elite adult women athletes with SUI, since it is assumed that 
elite athletes would respond to the treatment in the same way as other women do. 
However, given the non-stop impact on their pelvic floor, they may need stronger PFMs 
than non-adult athletes (26,29). 
In addition, the use of IVR is increasingly wider in the field of rehabilitation, which is 
important to assess the effectiveness of this new technology for future designs and 
uses. It can also be a work tool that allows to maintain and / or increase the frequency 
of treatment without the need to attend the rehabilitation centre (40). The protocol 
presented in this study, up to the knowledge of the author, will be the first RCT on the 
use of this new technology in the field of urinary incontinence.  
The aim of this study is to evaluate, for the first time, the effectiveness of PFMT in 
female elite adult athletes with SUI using an immersive virtual reality program in order 
to reduce the urine leakage and improve the quality of life of these population.   
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3 HYPOTHESIS 
Stress urinary incontinence treatment in elite female adult athletes using a program 
which combines PFMT and BF with IVR is more effective in improving quality of life 
than the conservative PFMT treatment with biofeedback alone.  
4 OBJECTIVES 
4.1 PRIMARY OBJECTIVE   
To evaluate the effectiveness of PFMT using immersive virtual reality for stress urinary 
incontinence based on quality of life in adult women elite athletes compared to normal 
care.   
4.2 SECONDARY OBJECTIVES   
To assess the effect of PFMT using immersive virtual reality for stress urinary 
incontinence compared to normal care on:    
 Urine leakage  
 Incontinence severity  
 Muscular strength of the pelvic floor  
 Treatment adherence  
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5 METHODOLOGY 
5.1 DESIGN 
The study is a randomized controlled double blind trial. It is a pre-post study with follow-
up at three, six and twelve months. It follows the Checklist SPIRIT 2013 (44).  
The aim of the study is to evaluate the effectiveness of a health intervention based on 
the idea of secondary prevention, since it is applied to patients with a base pathology, 
in this case, female adult elite athletes with SUI.  
The present study divides the sample into two groups; a Control group and an 
Experimental group. The first group (control group) will follow a conservative protocol 
of PFMT with biofeedback using a game application. It will be named as “Group 1”.  
The second group (experimental group) will follow the same protocol of PFMT with 
biofeedback through an immersive virtual reality program using the same game 
application. It will be named as “Group 2”.  
The volunteers women athletes, recruited from Sant Cugat CAR, who comply the 
inclusion criteria will be given a link of the web platform “Open Clinica (annex 12.1)” 
(45) to sign in, in order to participate in the study. The distribution of the patients to the 
groups will be randomized by the same online platform “Open Clinica”. Each patient 
will introduce her social security number to the program an automatically they will be 
classified in Group 1 or Group 2. The randomization of the trial will be done to avoid 
selection bias in order to realize a valid statistical analysis and to guarantee that the 
randomization allows creating two groups with similar and comparable characteristics 
thus all the participants will have the same possibilities to receive an intervention or 
the other. 
Once they have been signed in, Open Clinica will inform the patient when and where 
will be the treatment. Group 1 will be treated in a sport facility from Sant Cugat CAR 
(separated with room dividers) and Group 2 will be treated in another sport facility from 
the same place. The results of the randomization will be registered in Open Clinica 
folders, only accessible by the computer technician, without specifying if they are 
Control group or Experimental group.   
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Participants will be blinded because they won’t know in which group they are, the 
experimental or the control group. The physiotherapists who will treat the patients will 
be external from the intervention, and they won’t know which is the control group and 
which is the experimental group, but they will know which therapy they have to carry 
out.  
The patients’ follow-up will be done through various assessments. The first 
assessment will be at the beginning of the study (enrolment) for all participants in order 
to confirm the inclusion criteria. The variables will be assessed, both from the 
experimental group and for the control group, firstly on Monday, September 3, 2018. 
Next assessments will be after three months (QoL, urine leakage, incontinence 
severity, and PFMs strength), six months (treatment adherence) and twelve months 
(all the variables).  
During the first two weeks, participants will carry out the intervention with the presence 
of the physiotherapist. Afterwards, the patients will continue with the treatment without 
him/her. It will be patients’ responsibility to attend the place and at the time of treatment 
during the following 12 months of the study. 
5.2 STUDY SUBJECTS 
In this study the target population will be the adult elite women with SUI from a High 
Performance Center, specifically from the Sant Cugat CAR.  
According to the Spain Sports Council, it is defined as an elite athlete those who have 
been accredited as such, by resolution of the President of the Sports Council. The 
characteristics of high level athletes are published in the BOE “Real Decreto 971/2007, 
de 13 de julio, sobre deportistas de alto nivel y alto rendimiento” (46).  
It is important to highlight that before doing the study, the author has contacted via 
email with the physiotherapist in charge at the Car Sant Cugat, Marta Bou, and she 
reported that unfortunately many sportswomen from the Sant Cugat CAR suffer from 
this condition but few talk about it, so the physiotherapist stressed that it is a pathology 
which is hardly treated but it should be.  
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To ensure that both groups (control and experimental) are heterogeneous and that the 
results are not due to the homogeneity, sociodemographic characteristics will be 
collected at the baseline (annex 12.2) (47,48). 
For the estimation of the sample size, the Calculus Mostral Granmo (49) will be used, 
which will carry out the calculation of the sample by contrast of hypotheses and through 
the comparison of two independent means. The sample size calculation is based on 
the study of Sjöström et al. (47). It is assumed that a reduction of 2.52 points in the 
International Consultation on Incontinence Questionnaire – Short Form (ICIQ-SF) will 
be sufficient to be considered clinically relevant (50).  
Accepting an alpha risk of 0.05 and a beta risk of 0.2 (statistical power of 80%), using 
a two-sided test, and assuming 15% withdrawal rate, it will be necessary to include 32 
subjects in each group to detect a difference greater than 2.52 units (assuming a 
baseline distribution of 3.3 (47)).  
As mentioned before, an external computer technician will be the responsible to keep 
the assignments using Open Clinica, on a computer assigned to this study that is 
inaccessible to the rest of the study staff. 
5.2.1 INCLUSION CRITERIA  
- Urodynamic SUI (urethral closure pressure equal to or greater than 20 cm of 
water) 
- ICIQ-SF questionnaire > 0  
- Adult elite woman athlete 
- Nulliparous  
- Signed Informed Consent 
5.2.2 EXCLUSION CRITERIA  
- Detrusor over activity  
- Neurological diseases (such as multiple sclerosis, involvement of some 
nerve…) 
- Muscular diseases (such as infections, inflammations…) 
- Anomaly genital bleeding  
- Pelvic organ prolapse (uretrocele, cistocele, rectocele, enterocele, uterine 
prolapse, vaginal dome prolapse, rectal prolapse) 
- Active genital infections 
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In addition, few women who report UI symptoms (and/or prolapse) are as well affected 
by another serious condition. Because of that, the National Institute for Health and 
Care Excellence (NICE) created a Guidelines for Investigation of Urinary Incontinence  
in order to identify red flags and immediately refer to a specialist (51,52).  
For UI, indications for urgent referral are (51,52):  
- microscopic haematuria in women aged over 50 years  
- visible haematuria  
- recurrent or persisting urinary tract infection associated with haematuria in 
women aged 40 years or over  
- suspected malignant pelvic mass  
Besides, NICE guidelines indicate that referral should be considered in cases of  
(51,52):  
- Persisting bladder or urethral pain  
- Clinically benign pelvic masses  
- Associated faecal incontinence  
- Suspected neurological disease  
- Symptoms of voiding difficulty  
- Suspected urogenital fistulae  
- Previous continence surgery  
- Previous pelvic cancer surgery  
- Previous pelvic radiation therapy  
All the symptoms and / or pathologies mentioned in the previous paragraphs, will be 
considered as exclusion criteria. 
In order to ensure that the patient meets the inclusion criteria and does not present 
any exclusion criteria, the physiotherapist responsible to carry out the treatment and a 
urogynecologist, will perform the first day (the same day participants sign the informed 
consent) an urogynecological anamnesis (annex 12.3). 
If during the trial any physiotherapist, notices any of these symptoms mentioned 
before, the treatment must stop and the patient is excluded from the study. A table of 
recommendations summary is shown at the annex (annex 12.4) (51). 
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At the time the subjects meet these criteria, they will receive a fact sheet (annex 12.5) 
and will sign the informed consent (annex 12.6), based on the Declaration of Helsinki 
(53), where the study and its purposes are explained in addition to the approval of the 
study by an Ethical Committee. 
5.3 STUDY VARIABLES  
5.3.1 TYPES OF OUTCOME MEASURES 
 
 International Consultation on Incontinence Questionnaire-Short Form 
The Second International Consultation on Incontinence, settled up a new questionnaire 
that identifies people with urinary incontinence and the impact on the quality of life 
(QoL): the International Consultation on Incontinence Questionnaire (ICIQ). Besides, 
it was developed one short version of this questionnaire with the objective to be used 
both in research studies and in the clinical practice: ICIQ short form. Its final version, 
which has been translated and culturally adapted in various countries, consists of 3 
items («frequency», «quantity »and« affectation »), plus a group of 8 questions related 
to the type of UI with only the purpose to describe and guide on the type of UI (54). 
ICIQ-SF is the first questionnaire designed for diagnosing UI validated in Spain.  
“The psychometric properties of the ICIQ-SF are satisfactory and allow to recommend 
the use of the questionnaire in the clinical practice” (54). 
The total score of the sum of the first 3 items, goes from 0 to 21 points (annex 12.7). It 
is considered UI diagnosis any punctuation > 0 (54).  
It is stablished that the minimal important difference to consider clinically relevant 
improvements post-treatment in women with SUI is 2.52 (50).  
 Pad test  
The ICS proposes the use of the called "Pad Test" or "Test of the Compress" to 
measure urine leakage (55,56). 
This test is carried out over an hour, with the bladder full and after ingesting a volume 
of 500 cl of water in a maximum period of 15 minutes (55). 
At half an hour, the patient must perform the following activities: climb a floor of stairs, 
get up and sit down ten consecutive times, cough ten times, run on the same spot for 
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a minute, bend over to take an object from the ground five consecutive times, and 
finally wash hands in cold water during a minute (annex 12.8)  (55). 
The compress is weighed in a digital scale before and after the exercises to quantify 
the urine leakage. Weight differences of + 1 or + 2 g are considered normal since they 
can be due to the sweating itself of the perineum or to vaginal discharge. An increase 
of 2 to 10 g are considered mild incontinence, 11 to 50 g represents moderate 
incontinence and > 50 g means severe incontinence. In this study, results post-
treatment of 1 g or less will be noted as cured, while 50% or more decrease in wet 
weight will be considered as improvement (55–57).  In a study performed by Sutherst 
et al. (55) in a population of 100 and 50 continent women, the average loss of urine 
following the Pad Test was 0.8 g in patients with normal control of the urine, 25.7 g in 
women with stress urinary incontinence and 20.7 g in patients with urgency urinary 
incontinence; they also observed that while the patients with stress incontinence 
suffered an average of 5-6 leaks during the duration of the test, women with urinary 
urgency only referred 1-2 urine losses (55).  
Although it is published that in long-term Pad Tests (more than an hour test) the 
correlation between the test and the severity of incontinence is better, a number of 
variables can affect its validity (hormonal status, environmental conditions, physical 
activity level and the type of pads used). Furthermore, the short-term shows a good 
correlation with a self-assessment questionnaire (55) .  
 Incontinence severity index (ISI) 
“It consists of two questions regarding frequency and amount of leakage. It categorizes 
urinary incontinence into moderate, severe, and very severe” (58). 
The validity of the questionnaire is equally demonstrated in primary and hospital care 
(annex 12.9) (58).   
 
 Perineometry  
 
Laycock developed and validated a valuation palpation protocol called PERFECT  
(P= power, E=endurance, R= repetitions, F= fast, ECT = every contraction timed) to 
evaluate the strength of pelvic floor muscles. The present study will use the Modified 
Oxford Scale or Laycock Scale to measure strength (55,59,60) .  
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- Power: Measured on a modified Oxford scale during a maximal voluntary 
contraction (MVC).  
- Endurance: Expressed as the length of time, up to 10 seconds, that a MVC can 
be sustained until a detected strength loss of 35-50%. A simultaneous 
contraction of hip adductors and glutei and the stronger co-contraction of 
transversus abdominis could indicate the fatigue of PFMs. Breathe-holding 
should be avoided so if it is detected the physiotherapist should instruct to 
contract the pelvic floor on expiration.  
- Repetitions: Number of repetitions, up to 10, of MVC with a rest time between 
contraction and contraction of 4-6 seconds. On the practice, once the patient is 
able to contract 10 repetitions of 10 seconds MVC, the rest time could be 
reduced.  
- Fast: Number of fast contractions of one second until the muscle fatigues, with 
a maximum of ten (after a short rest at least one minute). The patient will be 
instructed to “contract-relax” as quickly and strongly as possible.  
- Every Contraction Timed: Reminds the examiner to time and record the above 
sequence of events so that the exercise program of each patient is performed 
in an individualized and specific way.  
 
During the assessment of pelvic floor muscles contraction, the physiotherapist should 
pay special attention to the presence or not of parasitic contractions, mainly of the 
abdominal muscles, adductors and buttocks. If the physiotherapist detects these 
synergies during muscles assessment, he/she must place the hand on the abdomen 
of the patient, in order to feel any muscular contraction of this region, at the same time 
that he/she can observe possible contractions at the level of thighs and buttocks (55). 
  
However, the perineometer is the most used objective test in all the analysed studies 
(56,61). As in the palpation evaluation, in perineometry can also be applied the 
PERFECT protocol in instrumental assessment, with the advantage that it can be done 
not only in the gynaecological position, but also in sitting and standing (55). 
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GRADE MUSCULAR RESPONSE DEFINITION 
0 Nothing No discernible muscle contraction 
1 Flicker Trembling movements of the musculature 
(<2” contraction)  
2 Weak Weak pressure without flicker but without 
any discernible lift (≥ 3” contraction) 
3 Moderate Increased pressure and slight elevation of 
the posterior vaginal wall (4-6” x 3 times) 
4 Good The examiner’s fingers are tight firmly; lifting 
the back wall of the vagina against 
moderate resistance (7-9” x 4/5 times) 
5 Strong Holding with fingers strength and lifting of 
the back wall against a maximum 
resistance; the examining finger is 
squeezed and drawn into the vagina (≥ 10” 
x 4/5 times)  
Table 2: Modified Oxford rating scale for the pelvic floor musculature; Laycock (55,59,60).  
PERINEOMETER (MM HG) LAYCOCK VALUATION SCALE (GRADE) 
0-30 1-2 
30-40 3-4 
50-60 5 
>60 5+ 
Table 3.  Approximate equivalences between the scale of Laycock assessment and the pressure measured by the 
perineometer in mm Hg (55). 
 Treatment Adherence 
Adherence is defined by the IUA and the ICS as (62):  
“The extent to which a client/patient's behaviour corresponds to the agreed treatment 
protocol and/or regime as recommended by their healthcare provider. It does not refer 
to the intervention itself; rather, the patient's commitment to undertaking the behavioural 
change to adhere to the intervention” 
To measure treatment adherence it will be taken into account the times the participant 
access to the game application and carry out the exercises stablished. Each time the 
patient accesses the application, it is registered with a patient number and the date.  
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5.4 DATA COLLECTION AND ANALYSIS  
The data collection will be done through the electronic platform Open Clinica and will 
be based on a Good Clinical Practice Standards Course (BPC) published on May 17th, 
2011 by the Central Unit of Clinical Research and Clinical Trials of the University 
Hospital of Vall d'Hebron" (45,63). The Open Clinica date base will contain the 
variables: QoL punctuation measured with ICIQ-UI SF test, grams of urine leakage 
measured with Pad Test, incontinence severity measured with ISI test, pelvic floor 
muscle strength measured with perineometry and treatment adherence measured by 
the times the patient access to the game application. Those responsible for collecting 
the results of the measures will be physiotherapists external from the study. 
The data collection will basically contain a sheet with personal data of the patient, the 
anamnesis and an assessment of the variables to be studied with the corresponding 
measurement tools previously explained. The information (personal data and 
anamnesis and the specific tests) will be collected before starting the study, both from 
the experimental group and from the control group, and then at three, six and twelve 
months, as it has previously been explained on the design.   
These data will be stored without risk of disclosure in accordance with the privacy and 
data protection of patient's law and the Catalonia physiotherapy deontological code 
(64).  
5.5 GENERALIZATION AND APPLICABILITY 
In the event the results of the study conclude that the treatment by pelvic floor muscle 
exercises combined with BF using immersive virtual reality on elite adult women 
athletes, is more effective than conservative treatment with PFMT with BF alone, infer 
could be done using the presented protocol treatment to patients who stop the 
treatment due to boredom or lack of motivation. The present study is carried out in a 
specific population, adult women elite athletes, since it is a type of population highly 
susceptible to suffer the pathology. In addition, until now there are no RCTs with a 
good methodological quality on PFMT treatment for SUI in this type of population. To 
make a generalization of the results and justify their applicability within the health 
sciences, a larger sample of patients would be needed. More financial resources would 
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also be needed to provide patients with their own virtual glasses and a BF so that they 
could perform the treatment from their home. 
Although the selected population is very specific in terms of the amount of sport they 
perform, it would be possible to extrapolate the results to women in adulthood who 
suffer from stress urinary incontinence without taking into account the sport practice. 
Likewise, it would be a new bibliographical contribution for physiotherapy, although 
other studies are needed to confirm the hypothesis through replicas of it. 
Generally, the current scientific culture assumes that negative results are not worthy 
of attention. However, Matosin et al. (65) present another perspective about this fact. 
They assume that scientists’ duty is: publish all date because negative findings are still 
important findings and have a hypothesis to explain the finding.  
“Only then can we work towards an improved scientific paradigm” (65).  
To sum up, in the case of obtaining contradictory results to the exposed hypothesis, it 
would also be useful, since it could confirm that the use of this expensive therapy would 
not be significantly effective in SUI treatment in respect to the treatment currently used 
in the centres of health. In this way, the conclusion would be that more studies of 
alternative therapies are needed for those patients, previously commented, who have 
difficulty to follow the treatment without ceasing it.  
5.6 STATISTICAL ANALYSIS  
 
All the data obtained during the study collected in Open Clinica will be exported to the 
statistical program SPSS (Statistical Package for the Social Sciences) in order to 
perform the analysis of all the variables in the study. The univariate and bivariate 
descriptive analysis will be applied in the first place. For the univariate analysis, 
frequency tables will be made. Quantitative variables will be described using measures 
of central tendency (mode, arithmetic mean and median), measures of position 
(quartiles and percentiles), measures of dispersion (amplitude, range interquartile, 
variance, standard deviation), and measures of shape (normal distribution, asymmetry, 
pointing) (66).  
To facilitate the reading of the results, it will be used different graphical representations, 
such as the histogram and frequency polygon for the quantitative ones or the bar 
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diagram for the qualitative ones. In the bivariate analysis, it will be used the 
contingency tables and the comparison of frequencies using the Pearson Chi-square 
test (qualitative), the dispersion diagram and Pearson's linear correlation coefficient 
(quantitative), comparison of the means (T-Student, qualitative-quantitative). Once the 
descriptive part is done, it is needed to know the evidence provided by the data for or 
against the proposed hypothesis. For this, it will be used the test of statistical 
significance or hypothesis contrast in order to reject the null hypothesis (H0), to accept 
the alternative (H1) (66).  
H0 = Stress urinary incontinence treatment in elite female adult athletes using a 
program which combines PFMT and BF with IVR is not more effective in improving 
quality of life than the conservative PFMT treatment with BF alone. 
H1 = Stress urinary incontinence treatment in elite female adult athletes using a 
program which combines PFMT and BF with IVR is more effective in improving quality 
of life than the conservative PFMT treatment with BF alone.  
The differences between the groups will be contrasted using Student’s-test or the 
Mann-Whitney test when assuming a non-normal distribution. Regarding statistical 
inference, it will be assumed a 95% confidence interval, with an α value of 0.05, that 
is, a 5% error α (66).  
A group appointed by the study sponsor will carry out the statistical analysis. It will 
include at least one specialist in biostatistics and methodology independent of the 
research. 
The results will be analysed before the treatment, after 12 weeks, 6 months, and 12 
months.  
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5.7 INTERVENTION PLAN  
 
The intervention is based on an European project called “WOMEN-UP” developed by 
a consortium composed of eight partners from six EU countries. According to the 
responsible: 
“The main objective of the WOMEN-UP project is to improve the quality of life of urinary 
incontinence patients through a holistic and cost-effective ICT-solution for a 
conservative home treatment, allowing for the self-management of the chronic UI 
disease via a decision support system and a secure remote medical supervision” (67).  
 
The aim of the present RCT is to create a treatment protocol based on WOMEN-UP 
with the addition of IVR specifically to be applied to elite women athletes, with the 
possibility of extrapolating it to any woman with SUI. The computer technician of the 
study will design a game application that can be used in a computer, mobile, tablet, 
etc. Both the control and experimental groups will use the application to carry out the 
treatment. The application will include different exercise programs that could be 
designed individually for each patient depending on the results of the first assessment 
in the PERFECT protocol. The specificity is given by the IVR game. 
The IVR will provide individual experience activity based on real-like sport. Every 
women (experimental group) will have the possibility to strengthen her pelvic floor 
muscles in an “immersion” of her competition sport with the objective that the acquired 
skills transfer to the real world. As Bø (32) reported, in order to reach an automatic pre-
contraction during specific physical stress before the increase of intra-abdominal 
pressure. The application designed name will be “TRAIN-TO-PLAY” (TTP).  
5.7.1 SYSTEM CHARACTERISTICS  
 
The project consists on creating an application with pelvic floor muscle rehabilitation 
games using immersive virtual reality glasses. It will include an intravaginal device that 
can be connected wirelessly or via Bluetooth to a computer / television / tablet /mobile 
phone, etc.  
The device should work with the biofeedback, that is, the biofeedback is a technique 
used to control the physiological functions of the human organism, through the use of 
a feedback system that informs the subject of the state of the function that is want to 
control voluntarily. 
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Device summary: 
 Intravaginal device with connection wirelessly or via Bluetooth to a computer / TV / 
tablet / mobile phone, etc. as well as immersive virtual reality glasses.  
 The device works as a clinical biofeedback. 
 The device transmits the information received, based on PERFECT protocol, to the 
TTP app that is connected monitoring through a graphic interface.  
 The challenge of the Immersive Virtual Reality sport is a specific rehabilitation 
program established by the physiotherapist based on patient’s needs.  
 The physiotherapist is able to customize the challenge game. 
 The IVR program could include advice from the physiotherapist. 
 The TTP app record each patient’s training.  
 The app allows the patient to follow up the training at home and the therapist can 
access the app to observe rehabilitation progress without the need for the patient 
to assist consult. 
 It is a way to continue with the long-term treatment because the appointment with 
the physiotherapist is not necessary since through the app they can be in contact. 
 The app and the device allows the patient to choose whether she wants to train 
with IVR or whether she wants to train without IVR. 
Currently, already exists an immersive virtual reality rehabilitation system with 
biofeedback called “VAST.REHAB” classified as a medical device, and it received CE 
marking conforming to the regulatory system of the EU’s medical device directives. 
Although the system allows its use in many conditions (cerebral vascular accidents, 
multiple sclerosis, cerebral palsy, parkinson’s disease and extrapyramidal syndromes, 
brain tumours operations, spinal cord injury, traumatic brain injury, muscular atrophy, 
muscle weakness due to lack of mobility, endoprothesis, stable fractures, limb 
amputations and balance and equilibrium disturbances) it does not include the 
possibility to treat urinary incontinence condition (68). So the idea of TTP app is to 
create an app based on “VAS.REHAB” characteristics but designed for UI treatment.  
5.7.2 SYSTEM ARCHITECTURE  
 
The architecture of the device is already developed in a final master assignment of the 
“Universitat Politècnica de Catalunya” but it has not been tried out yet, so it will try to 
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contact with the author and the tutor of the work to use the project of the device 
including the new characteristics of immersive virtual reality (16).  
The following diagram shows the general structure of the proposed system: 
5.7.3 FIRST ASSESSMENT  
 
Both groups will receive a first appointment which will consist on: 
1. Patient education: Make the patient understand her condition in order to 
empower her to play an active role in her treatment.  
2. Learning the contraction: Teach how they should perform pelvic floor muscle 
training.  
3. Physical exploration by the physiotherapist  
4. Establish the treatment  
 
 
Figure 11. Diagram of the project architecture. 
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1. PATIENT EDUCATION:  
It is important to explain the patient the importance of her condition in order to make 
her active to the treatment. Having passed two weeks of the treatment, the patient will 
have to continue with the PFMT by her own so it is important to show the relevance of 
SUI (62).  
2. LEARNING THE CONTRACTION:  
First of all, the physiotherapist will do a digital palpation to explain the patient how to 
contract PFMs. The patient is positioned supine on a stretcher with knees flexed and 
abducted hips. Next, the professional will place the index or the index and the middle 
finger, within 4-6 cm of the vaginal introits and teach the patient how to do the 
contraction avoiding abdominal contraction (61).  
During the first two weeks participants will carry out the treatment with the presence of 
the physiotherapist in order to make sure that the contraction is done correctly.  
To make sure that all the physiotherapists teach the same way, they will have a 
standard guide with some expression tools (69): 
- “Lift the pelvic floor up from the surface by pulling up and contracting around the 
urethra, vagina and rectum. Squeeze so hard that you feel a slight trembling in 
your vagina. When you squeeze hard enough, you can feel the lower part of the 
stomach being pulled in slightly at the same time. Try to feel the difference 
between relaxing and tightening the pelvic floor”. 
- “Try to stop the flow when you are urinating. If these muscles are weak, it may 
be difficult to stop the flow when it is strongest. Do not use urination for training, 
as this can interfere with the ability to empty your bladder completely”.  
3. PHYSICAL EXPLORATION (55):  
a. Visual exploration:  
i. State of skin: The presence or not of abrasions, erythema, mycosis, 
vesicles or leucorrhoea that could indicate an infection, in whose case 
the treatment will be suspended immediately and it will be referred to 
the gynaecologist. 
ii. Colour: Gives an idea of vulvovaginal trophicity, main sign of the 
oestrogen level. In the case that it is detected a very pale coloration 
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of the mucosa, with a pearly colour and a loss of elasticity in the labia 
minora it is convenient to derivate the patient to the gynaecologist to 
assess the need of an estrogenic treatment, since the level of 
hormones can greatly influence the ability of contraction of the 
perineal musculature and in the success of the physiotherapy 
treatment. 
iii. Opening vagina diameter and ano-vulvar distance: Under normal 
conditions, the introit vaginal is closed in the resting state, except of 
multiparous women presenting a slight opening. It is considered a 
normal opening when the diameter of the vaginal introit does not 
exceed 25 mm. Distance ano-vulvar measures the length of the 
tendinous centre of the perineum, insertion point of the perineal 
musculature, whose normal length is between 2.5 and 3.5 cm.  
b. Palpation: The palpatoria exploration brings to the physiotherapist a great 
relevance information about the state of the muscles and joints of the pelvis, 
as well as the static of the organs of the pelvis. By palpation could be 
assessed the tone of the perineal muscles, posterior and anterior walls of 
the vagina, the urethra, and the degree of mobility of the coccyx.  
 
Remember that before beginning the treatment the physiotherapist has already carried 
out an urogynecological anamnesis. As previously mentioned (section 5.2.2), the 
presence of any of the symptoms considered as red flags will immediately force to stop 
the study and refer the patient to a specialist. 
 
4. ESTABLISH THE TREATMENT:  
The first assessment to establish the treatment will be done by a perineometer. 
Perineometry is defined as “measure of strength generated via change in pressure within a 
balloon connected to a pressure sensor” (61). 
 
In SUI the urine leakage is correlated with pelvic floor muscle strength, so the treatment 
will be based on the strength parameter.  According to a metha-analysis, measuring 
strength by digital palpation using the Muscle Strength Oxford Scale must be 
considered subjective due to differences among technicians’ interpretation (8), that is 
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why it is decided to measure the strength by perineometry.  However, there is no 
current “gold standard” to quantify PFM strength in females with UI (61).  
In the present study, it will be used the 
trademark Peritron of LABORIE Medical 
Technologies Canada. It disposes of three 
different sensors but the author will only use 
the vaginal sensor. In order to ensure that all 
professionals use the instrument correctly, 
they will be dispensed  the manual Peritron 
Owner's Manual V07 PERI-UM01 where it is 
detailed how to make a good use of Peritron.  
There is no standard protocol for the 
treatment of pelvic floor exercises because it is an individualized treatment based on 
the results of the first assessment. The literature indicates a lack of standardisation 
and so it is studied that a uniform, standard regimen is not appropriate. Instead, it is 
proposed to progress sequentially as power and endurance increase. It is established 
that 8-12 repetitions close to maximum during 6-8 seconds with 6 rest seconds, is 
considered a quiet good contraction (1,60,70).  
It is relevant to highlight that the physiotherapists responsible for teaching the 
treatment (P1) and the physiotherapist responsible for evaluating the variables (P2) 
will be qualified and specialized in pelvic floor treatment. P1 will be responsible for 
establishing the treatment needed in each patient.   
The treatment will be the following:   
 CONTROL GROUP:  
 Pelvic Floor Muscle Training  +  biofeedback with “TTP“ app  
 
The first day of treatment:  
1. Pass the ICIQ-SF questionnaire.  
2. Develop Pad Test. 
3. Pass the ISI questionnaire.  
4. Perineometry assessment to measure muscle strength and to establish the 
treatment based on PERFECT results. 
Figure 12. Peritron device 
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Duration of each session: There is not enough evidence about the duration of each 
physiotherapy therapy session, but analysing different systematic reviews, most of the 
studies stablished between 20 and 45 minutes so it will take on an average of 30 
minutes each session (1,3,71).  
Positions: lied, biped, kneeled, and sited with legs apart to emphasise specific strength 
of PFMs and relaxation of other pelvic muscles. Firstly, the patient will start the 
treatment lied, as the sessions go by and the contraction improves, the physiotherapist 
could consider other contraction positions (1).  
Frequency: 3 times per week (1). It has been considered that three times per day will 
be too much in order to follow up the treatment adherence.  
Duration: 2 weeks with the presence of the physiotherapist (P1) and then until 12 
months without his/her presence to simulate they are training at home. Even though 
the study finishes at 12 months, once they have finished the study, it should be given 
a firmly recommendation to keep doing PFMT every day at home (1,70).  
 EXPERIMENTAL GROUP  
 Pelvic Floor Muscle Training + biofeedback with “TTP“ app  
 Immersive Virtual Reality  
The protocol will be the same as in the control group, the difference will be that the 
experimental group will perform the exercises through a sports-game using immersive 
virtual reality glasses with TTP app. The sport will first be chosen by the 
physiotherapist, based on the sport in which the patient competes to try to apply the 
acquired skills to the real competition. Once the contraction has improved, the patient 
can choose different games to practice. 
The position, frequency and duration will be as in the Control group.  
As it has been mentioned before on the “system characteristics”, the TTP app allows 
connecting IVR or performing the exercise without IVR. In that way, it ensures that the 
same goals could be achieved with the Control and the Experimental group and so it 
allows to use the same application to develop the treatment in each group.  
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6 CALENDAR 
Table 4.  Schedule of enrolment, interventions, and assessments SPIRIT (44).  
 
 
Analysis of the data, results and conclusions will be carried out 2 months after the end 
of the intervention. 
STUDY PERIOD 
 
Enrolment Allocation Post-allocation 
Close-
out 
TIMEPOINT** 
04/06/18-
20/08/18 
27/08/18 t1= 03/09/18 t2= 14/09/18 t3= 03/12/18 t4= 04/03/19 t5= 03/06/19 
ENROLMENT:    
 
   
Eligibility 
screen 
X   
 
   
Informed 
consent  
X   
 
   
Anamnesis X       
Allocation  X      
INTERVENTI
ONS: 
   
 
   
[Group A]   
     
[Group B]        
ASSESSMEN
TS: 
   
 
   
QUALITY OF 
LIFE 
X  X 
 
X  X 
URINE 
LEAKAGE 
X  X 
 
X  X 
INCONTINEN
CE SEVERITY 
X  X 
 
X  X 
MUSCULAR 
STRENGHT 
X  X 
 
X  X 
TREATMENT 
ADHERENCE 
  X  X X X 
With physiotherapist supervision  
Without physiotherapist supervision 
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7 LIMITATIONS AND BIAS  
Occasionally, limitations may arise that must be taken into account, as they could 
directly influence the final results of the project. 
First of all, one of the basic restrictions of the project is the difficulty in meeting the 
number of participants that the project requires, since it is a pathology that is still 
somewhat "taboo" and patients have difficulties in accepting it, either by fear, by shame 
or simply because they do not consider it as an important pathology. 
Another limitation is the possibility for patients to give up the intervention due to 
external causes. Although this fact is taken into account on the size of the sample, if 
there are more cessations, the results could be affected. 
In the selection of the measurement tools of the project, it has been chosen those tools 
validated and used in numerous scientific studies and recommended by the European 
Association of Urology. However, there are disadvantages in the use of some selected 
measuring instruments, mainly due to the possibility of error in the measure between 
the different observers (physiotherapists). This is what happens in the case of the 
Perineometer. It is the most objective method that reports the scientific literature to 
assess muscle strength, but nevertheless, it has limitations in its use. Due to its shape 
(Figure 12. Peritron device), it is difficult to ensure the exact positioning of the perineometer 
because it is very sensitive to the movement and does not adhere to itself, requiring 
the physiotherapist to hold the utensil while evaluating the patient. After observing the 
bias in the use of the perineometer during my 
university clinical practice, as happens with 
biofeedback, a proposal future line could be the 
creation of a biofeedback catheter similar to the 
electro-stimulation one (section 7.1) to allow its 
use without having to be subjected.  
It is necessary to point out that, as previously 
explained (section 1.4), that SUI may be due to 
either urethral hypermobility or intrinsic sphincter 
deficiency. In the first case, urethral hypermobility can be caused by a deficit in any of 
the supporting elements (muscles, ligaments, fascia, etc.). If the cause is muscle 
Figure 13. Electrostimulation catheter (73).  
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weakness, the treatment will result effective. However, in the event that it is because 
of ligamentous or fascial weakness, it may be assumed that the fact of gaining strength 
with PFMT does not necessary correspond to the decrease in urine loss, since in these 
cases the specialist should be referred and assess the surgical intervention. 
Finally it can be found bias of data collection, either because the patient provides us 
with incorrect information, forget information, subjectivity, confusion or mistrust, among 
others. 
7.1 FUTURE INVESTIGATIONS 
As mentioned above, the cylindrical structure of the BF/perineometer makes difficult to 
establish an exact assessment of perineal strength since the device is very sensitive 
to movement. After doing this project it is valued the idea of creating a BF with a similar 
structure to the vagina electrostimulation catheter probe that does not move. 
In addition, there is no evidence to differentiate urethral hypermobility due to muscular 
weakness or any other support structure. It should be done more research in this field 
in order to derive from the first instance those patients that require the assessment of 
a specialist and/or surgical intervention. On the other hand, the relationship between 
the loss of urine and the deficit of strength has not been established either. It would be 
very beneficial to study this relationship to objectively assess the effectiveness of 
PFMT to set up adequate treatment objectives.  
Furthermore, to date, there is no one standard questionnaire or test that fulfils all 
requirements for assessment of people with UI. Clinicians must evaluate the tools 
which exist, for use alone or in combination, for assessment and monitoring of 
treatment outcome (37).  
The last future line proposed is to perform the qualitative study of how the treatment of 
the pathology could make changes in sports performance.  
8 ETHICAL ASPECTCS AND DIFFUSION  
To ensure compliance with the applicable standards of research and human subjects, 
the IRBs / ECs [institutional review boards / ethical committees] will review and approve 
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this protocol and the informed consent form (annex 12.6), based on the Declaration of 
Helsinki (44,53). 
All the information related to the study (participants' data, reports, data collection, 
processors and administrative forms) will be safely stored in the site of the study with 
files blocked in areas with limited access to the responsible researcher and the 
computer technician. The protocol has previously described on the Design and also 
the means by which personal information is collected and kept safe (section 5.1). The 
Data Management Coordination Centre will oversee the process of data exchange 
between studies, with the contribution of the Data Management Subcommittee (44,53). 
8.1 ADVERSE EFFECTS  
It will be classified as an adverse effect any symptom reported by the patient as: 
discomfort, soreness, pain, bleeding or any synonym. Cochrane systematic reviews 
do not report any adverse effect on their studies about PFMT treatment on SUI (3,9).  
In the use of biofeedback, will be an adverse effect any event such as pelvic pain, 
vaginal or anal bleeding, skin reaction or muscle discomfort. Cochrane literature 
reports on a SR that only few women dropped out the treatment because of adverse 
events. It is surprising that 14 studies from the review does not report any measure of 
it. Although the adverse effects with regard to BF are minor and none of them seem to 
be serious, therapists should be careful because BF involves some vaginal or anal 
procedure (5).  
About IVR, there is not literature about if there is any adverse effect on the use of this 
device to the treatment of SUI. However, the Cochrane systematic review “Virtual 
reality for stroke rehabilitation” reports few adverse effects across studies and those 
reported (transient dizziness, headache, and pain) were relatively mild (40).  
However, before the participation, the patient will have to sign the informed consent in 
to guarantee that the subject has voluntarily expressed her intention to participate in 
the research, after having understood the information that has been given, about the 
objectives of the study, the benefits, the inconvenience, the possible risks and 
alternatives, their rights and responsibilities presented on a fact sheet (annex 12.5). 
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All participants enrolled, will have the right to be compensated in case of negligent 
damages. Compensation will be incurred through the National Health Service (NHS).  
9 STUDY ORGANIZATION  
Researchers: They must comply with all the requirements of the protocol and they will 
be responsible for the accuracy and truth of the information obtained. Especially, they 
must ensure at all times for the best possible care of the patient. 
Physiotherapist: They must attest that the information is true, for which they must have 
all kinds of facilities from the research team to develop their work. The physiotherapist 
(P1) will be the responsible for carrying out the treatment the first two weeks.  
Evaluator: Will be an external physiotherapist (P2) to the investigation and will be 
assigned by the promoter. He/she will be the responsible to measure the requested 
variables on the dates established in the schedule (section 6) and note them on the 
date base “Open Clinica”.  
Promoter: It is the University of Lleida and will be responsible for ensuring compliance 
with the relevant legal standards. 
Monitoring procedures: Before initiating the study, in a meeting of researchers, a 
representative of the Promoter will review the protocol and the data collection 
notebooks with the researchers and other personnel involved in the study. During the 
study, the evaluator will visit the centre regularly, to compare the data collected and 
check adherence to the protocol and the Good Clinical Practice Guidelines. The 
investigator and trial staff should be available to assist the evaluator during these visits. 
No data revealing the identity of patients should leave the participating centre. 
Audit: In addition to the monitoring procedures, the study may be audited by the Health 
Authorities (during the study or even when it has been completed), to assess 
compliance with the Good Clinical Practice standards. If a Health Authority requests 
an inspection, the investigator must immediately inform the Promoter that this request 
has been made. 
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9.1 RECORD OF DATA AND PRESERVATION OF DOCUMENTS 
The researcher must complete the data collection notebooks provided by the Promoter 
and send the data as indicated at the beginning of the study. The data collected during 
the trial should be documented anonymously and dissociated, linked to a code (social 
security number), or to the initials of the patient if necessary, so that only the researcher 
can associate such data with an identified participant.  
For approximately 2 months, all the data obtained in the measurements, computerized 
and classified in Open Clinica databases, will be analysed using statistical tools. Once 
the results have been obtained, based on tests such as hypothesis testing, the results 
will be discussed and a series of conclusions will be drawn about the initial hypotheses 
proposed. 
The researcher will keep the original clinical documents of each patient of the study, 
which consist of all the medical and demographic information and a copy of the signed 
informed consent form, for at least 15 years after the conclusion or suspension of the 
study. By signing the protocol, the researcher agrees to follow the procedures for 
document preservation. 
9.2 PUBLICATION CONDITIONS 
The results of the study will be owned by the University of Lleida, who will establish a 
publication policy through a committee. 
10 BUDGET 
To carry out the budget of the study, the resources have been divided into 3 groups: 
 Facilities and HR. 
 Material of Physiotherapy. 
 Office supplies. 
Table 5, 6 and 7 explain the expenses related to the human resources, to the 
physiotherapist’ material and to the office material needed, as well as the facilities 
used.  
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FACILITIES AND RRHH UNITS PRICE (€) TOTAL 
Local 2 
Ceded CAR 
Sant Cugat 
-  
Physiotherapist who 
carry out the treatment 
4 7,63/h x 192 1.464,96 
Physiotherapist who 
process the results 
4 7,63/h x 96 732,48 
Evaluator researcher 1 Voluntary -  
Biostatistics specialist 1 Ceded UdL -  
Computer technician 1 
1.000/month x 
12 
12.000 
SUBTOTAL - - 14.197,44 € 
Table 5. Facilities and rrhh budget  
MATERIAL UNITS PRICE (€) TOTAL 
Litter 32 
Ceded UdL and Car 
Sant Cugat 
- 
Litter paper 3 Ceded UdL - 
Exploration Gloves 3 Ceded UdL - 
Lubricating gel 2 6,05/100g 12,10 
Condoms 2 15,13 (pack 100) 30,26 
Cushions 30 
Ceded UdL and Car 
Sant Cugat 
- 
Sanitary towels 10 8,00 (pack 25) 80 
Room divider 8 Ceded UdL - 
Peritron 
(assessment) 
2 799,99/u 1.599,98 
Immersive virtual 
reality glasses 
2 200/u 400 
Immersive reality 
programme app 
1 
Created by the 
computer technician 
- 
BF with Bluetooth 
or Wi-Fi (treatment) 
4 800,00/u 3.200 
SUBTOTAL - - 5.322,34 € 
Table 6. Physiotherapist’s material budget  
OFFICE MATERIAL UNITS PRICE (€) TOTAL 
Laptop 2 445 € 890 
Open Clinica 
software 
1 
Ceded by the 
computer technician 
- 
Program SPSS 1 
Ceded by the 
biostatistics specialist 
- 
SUBTOTAL - - 890 € 
Table 7. Office material budget  
The sum of the 3 budget tables gives us a total of: 14.197,44 + 5.322,34 + 890 = 
20.409,78 €  
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12 ANNEX 
12.1 OPEN CLINICA 
 
Open Clinica produces cloud software that accelerates the investigation labour. It is an 
electronic data capture and data management which allows study oversight and 
monitoring and engage patients on their own devices (45). 
The platform does the randomization by its own and allows the researcher to choose 
weather a blinded or unblinded trial with unlimited treatment groups (45).  
It is validated by the certified quality system ISO, SSAE -16, the European Medicines 
Agency and by Food and Drug Administration (45).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
12.2 BASELINE SOCIODEMOGRAPHIC TABLE  
 
Characteristics Group 1 (n= 32) Group 2 (n=32) 
Age   
Body mass index (kg/m2)   
Height   
Weight   
Obstetric antecedents 
- Number of pregnancies  
- Repeated urine infections 
  
Pelvic surgical interventions   
Diseases: 
- Diabetes 
- Connective tissue diseases 
- Depression  
  
Smoking habit  
- Yes 
- No 
  
Hours per week of sport practice    
Type of sport practice 
- High-impact 
- Low-impact 
  
Medication 
- Yes (which)  
- No  
  
Constipation or cough symptoms  
- Yes 
- No  
  
Education 
- University studies 
- Less than university studies  
  
Table 8.  Baseline sociodemographic characteristics  (47,48). 
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12.3 UROGYNEACOLOGICAL ANAMNESIS 
Figure 14.  Pre-appointment patient history 
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Figure 15. Pelvic Floor Pathway Clinic 
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12.4 SUMMARY RECOMMENDATIONS 
 
Red flag Assessment Referral 
Haematuria 
General assessment:  
 Do you see blood in your urine?  
 
Urologist 
 
Urinalysis  
 Red blood cells (unresolved after 
treatment for UTI, or after contributing 
factor has ceased)  
 
Urologist 
 
Urinalysis  
 Proteinuria, red cell casts, or 
dysmorphic red blood cells and/or an 
elevated creatinine  
 
Nephrologist 
 
Palpable 
bladder/ 
symptoms of 
incomplete 
emptying 
Abdominal exam  
 Percussible bladder  
 Palpable bladder  
 Tenderness/pain in bladder  
 
Urologist 
 
Post-void Catheterization  
 Residual volume >150 ml  
 
 
Urologist 
 
Symptoms of 
neurogenic 
bladder 
Medical history  
 Neurologic disease  
 Spinal trauma  
 Diabetes  
 
further assessment 
 
Neurologic exam  
 Anal reflex  
 Anal sphincter tone  
 Saddle sensation  
 
Neurologist 
 
Pelvic Mass 
Urinalysis  
 Pregnancy test 
 
Gynaecologist 
Pelvic exam (including bi-manual)  
 Adenopathy  
 Ascites  
 Palpable mass  
 Costovertebral Angle tenderness 
 Compression of the cervix  
 Adnexal or uterine enlargement  
 Tenderness with vulvar or vaginal 
lesions 
 Rectovaginal compression or blood in 
the rectum  
 
Gynaecologist 
Table 9. Summary of Recommendations in UI assessment (51). 
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12.5 FACT SHEET FOR PATIENTS  
 
Title of the Study: “The effectiveness of Pelvic Floor Muscle Training through 
Immersive Virtual Reality for the treatment of Stress Urinary Incontinence based on 
the impact on the quality of life in adult women elite athletes” 
Promotor: Universidad de Lleida  
Introduction: 
Before you agree to participate in this study it is important that you read and 
understand the following information about the study and the procedures 
involved. If you have any questions about the study or your rights as a 
participant, do not hesitate to ask before taking your decision to participate. 
This document describes the objective, procedures, benefits, risks, discomforts and 
precautions involved in the study. Describes also the alternative treatments that are 
available to you and your rights as a participant. The results of the study cannot be 
guaranteed in any way. 
It is essential that you be completely frank about your medical history and any other 
symptoms or reactions you may experience during the study. If not, you could injure 
yourself for your participation in the study. Participation in this research study is 
completely voluntary, and you can refuse to take part in or withdraw from the study at 
the time you want without affecting your future medical care. Below, you can find more 
detailed information. It is important that you read this consent document before making 
a decision about your participation. 
Information on the background and objectives of the study: 
The Perineal Physiotherapy is a therapeutic discipline that allows to evaluate and treat 
pelvic floor dysfunctions (urinary and / or anal incontinence, perineal pain, prolapses, 
etc.) and others of the sexual sphere (dyspareunia, vaginismus, etc.) and that 
especially accompany to women in postpartum, menopause and man after prostate 
surgery. 
You have been invited to participate in this clinical research study because you suffer 
from stress urinary incontinence as a result of a long and demanding sport practice, 
affecting your quality of life to a lesser or greater degree.  
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In this circumstance, it is essential to try to strengthen the pelvic floor musculature in 
order to improve your quality of life; and this is the objective to which the treatment was 
fundamentally addressed. 
Like other physiotherapy specialties, perineal physiotherapy uses electrotherapy, 
biofeedback, manual techniques, perineal massage as a treatment, kinesiotherapy and 
behavioural techniques. Many of these procedures are intracavitary, that is to say they 
are intravaginal and/or ano/rectal. It should be done by specialized physiotherapists 
and with maximum hygiene guarantees, being intracavitary electrodes for individual 
use. The treatment does not guarantee the healing of the patient. 
There are several methods for the treatment of stress urinary incontinence. However 
what is more recommended and scientifically proven is the pelvic floor muscle training 
(PFMT). Unfortunately, it is a treatment which seem to be hard to follow and patients 
tend to give it up.  
The present study pretend to compare the effectivity of the PFMT with biofeedback 
and the addition of an immersive virtual reality (IVR) program in contrast to the 
conservative treatment (PFMT + biofeedback).  
None of the treatments carried out in the present study include pharmacology. 
Objective: Improve symptomatology and so the quality of life, and become aware of 
perineal muscles. 
Study procedure: 
Your participation in the study will last approximately 12 months. 
If, after having read this document, you agreed to participate, you will be submitted to 
the following study procedures today: 
 When all of your questions have been answered, you will be asked to write your 
name, sign and date this consent document. 
 The type of treatment that corresponds to it will be chosen at random: PFMT + 
biofeedback or PFMT + biofeedback and IVR.  
Study risks:  
 Most of the techniques used in perineal physiotherapy have no adverse effects.  
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 Occasionally it may cause discomfort or pain because of the biofeedback.  
 
You should warn the physiotherapist if you have a pacemaker implanted, suspected 
current infection or pregnancy, high blood pressure or any other process that may 
contraindicate the treatment. Will demand verbally how much information you need to 
understand. 
 
Benefits of participation in the study: 
You will not get any kind of benefit for participating in the study. However, the 
knowledge gained through your participation could help other people. 
 
Insurance / compensation: 
During your participation in the study, you will be covered by a civil liability policy 
contracted by the developer of the study that covers damages, as required by current 
Spanish legislation (RD223 / 2004). 
Confidentiality of information: 
Your identity, your hospital records and the information obtained in this trial are 
confidential, unless required by law, and will not be disclosed without your express 
written consent, to any person, except to the relevant staff of the study's promoters 
(University of Lleida), the Spanish health authorities and the clinical research ethics 
committee. If the results of this study are published, your identity will be kept 
confidential. By signing this document you are authorizing the researcher to provide 
your medical records related to your participation in the study, the sponsor, the relevant 
health authorities and the ethics committee. You can have direct access to the data 
and can request its revision according to the local legislation and procedures (Organic 
Law of December 13 Protection of Personal Data) of security measures of the 
automated data protection files. 
Voluntariness of participation: 
Participation in this research study is voluntary. You have the right to refuse to 
participate in the study or, if you participate, to withdraw from the study at any time, 
without affecting your future medical care. In addition, the investigator or the study 
sponsor may withdraw from the study without the need for consent, for any reason they 
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consider appropriate, such as, among others, an adverse effect that could place them 
at risk of further complications. 
Obtaining information: 
At any time you can ask the questions you want about the study. The investigator will 
provide you with his telephone number for any clarification. If during or after the study, 
you wish to discuss your participation in the study, or if you have any questions about 
the subjects of the research, your rights and/or about the injuries related to the study, 
you can contact.............................................................., researcher responsible for the 
study in the telephone number............................  
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12.6 INFORMED CONSENT FOR PATIENTS  
 
Title of the study: “The effectiveness of Pelvic Floor Muscle Training through 
Immersive Virtual Reality for the treatment of the impact on the Quality of Life of adult 
women elite athletes with Stress Urinary Incontinence” 
All data and personal documents will be stored and preserved with the utmost privacy 
and personal privacy complying with the Organic Law 15/1999, of December 13, 
Protection of Personal Data. Likewise, the director of the essay will be in charge of 
informing and answering all the doubts of the participants, as well as the way of contact 
in case of emergency or abandonment. 
Me___________________________________________________________with 
DNI_________________________ 
 I have read the information sheet that has been given to me 
 I have been able to ask questions about the study 
 I have received satisfactory answers to my questions 
 I understand that my participation is voluntary 
 I understand that I can withdraw from the study 
o When I want. 
o Without having to explain. 
o Without this having an impact on my medical care in any way. 
o I freely give my consent to participate in the study and I will receive a 
copy of this document. 
 
Therefore, I freely give my consent to participate in the trial; 
Barcelona, ____________________________ Participant signature. 
Barcelona, ____________________________ Researcher signature.  
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12.7 ICIQ – SF   
 
  
  
Figure 16. International Consultation on Incontinence Questionnaire (50,54). 
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12.8 PAD TEST 1H 
 
Table 10. Pad test 1 hour standardization (72). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PAD TEST 1 HOUR 
Time Physiotherapist work Patient work 
0 minutes Sanitary towel weight 500 ml liquid without Na 
30 minutes  Walk and go up stairs 
45 minutes  Stand up the chair x10 
Cough x10 
Run 1 minute 
Catch objects from the floor 
x5 
Handwashing 1 minute  
60 minutes Sanitary towel weight  
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12.9 INCONTINENCE SEVERITY INDEX  
  
Figure 17. Incontinence severity index questionnaire (58). 
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12.10 EAU RECOMMENDATIONS  
 
Figure 18. EAU Recommendations for behavioural and physical therapies (37).  
 
 
 
 
 
 
 
 
 
